Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +2.87%81 3-Year ROIIC % is 10.63 as of Dec. 2025, which is 22% below its 10-year median of 13.62. GuruFocus rates OSTO:MCAP with a GF Score™ of 81/100 and a GF Value™ of kr556.60 (Fairly Valued). Among 796 Medical Devices & Instruments companies, MedCap AB ranks better than 61.18% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
MedCap AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 10.63%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for MedCap AB's 3-Year ROIIC % or its related term are showing as below:
OSTO:MCAP's 3-Year ROIIC % is ranked better than 61.18% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs OSTO:MCAP: 10.63
MedCap AB (OSTO:MCAP) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
MedCap AB 3-Year ROIIC % Related Terms
MedCap AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for MedCap AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, MedCap AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where MedCap AB's 3-Year ROIIC % falls into.
MedCap AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 220.55656 (Dec. 2025) - 115.82396 (Dec. 2022) )
/
( 2077.9 (Dec. 2025) - 1092.5 (Dec. 2022) )
=
104.7326
/
985.4
=
10.63%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
MedCap AB (OSTO:MCAP) has a 3-Year ROIIC % of 10.63 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MedCap AB and its competitors. This is 22% below median its historical median of 13.62. According to the industry distribution chart, MedCap AB ranks #309 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 38.8%.
Is MedCap AB's 3-Year ROIIC % too high?
MedCap AB's current 3-Year ROIIC % of 10.63 is 22% below median its 10-year median of 13.62. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. MedCap AB's value of 10.63 is 556.2% above this industry median. Based on the distribution chart, MedCap AB ranks #309 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #309 out of 796 companies for 3-Year ROIIC %. This puts MedCap AB in the upper half of its industry. The industry median 3-Year ROIIC % is 1.62. MedCap AB's value of 10.63 is 556.2% above this benchmark. While the company's 10-year median is 13.62 vs. the industry median of 1.62, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current 3-Year ROIIC % of 10.63 is 556.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current 3-Year ROIIC % is 10.63, which is 22% below median its own 10-year median of 13.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr556.60, compared to a current price of kr519.50 — trading 6.7% below its estimated fair value. The current 3-Year ROIIC % is 10.63, which is 22% below median its 10-year median of 13.62 and 556.2% above the Medical Devices & Instruments industry median of 1.62. MedCap AB's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current 3-Year ROIIC % is 10.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr519.50 is trading 6.7% below its estimated GF Value™ of kr556.60.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
3-Year ROIIC %: 10.63 (22% below median its 10-year median of 13.62)
GF Value™: kr556.60 vs. price of kr519.50 (6.7% below fair value)
Industry Position: 556.2% above the Medical Devices & Instruments median (#309 of 796)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
81GF Score
Get the complete analysis for OSTO:MCAP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
